Galera Therapeutics 5/11/2026 Earnings Report

Galera Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.83
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Galera Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Galera Therapeutics Announcement Details

• Date: 5/11/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Galera Therapeutics (NASDAQ:GRTX) is a clinical-stage biotechnology company headquartered in Malvern, Pennsylvania. The company focuses on developing precision medicines designed to address oxidative stress and inflammation in pulmonary and rare diseases. Galera’s proprietary platform centers on small-molecule prodrugs of glutathione and related thiol compounds intended to enhance intracellular antioxidant defenses.

Galera’s lead product candidate is an inhaled glutathione prodrug currently in early-stage clinical trials for acute lung injury and acute respiratory distress syndrome. In addition to its pulmonary programs, the company is advancing research into supportive therapies for oncology patients and exploring additional indications where modulation of oxidative stress may offer therapeutic benefit. Galera employs both inhalation and systemic delivery approaches to optimize tissue targeting and pharmacokinetics.

Founded in 2013, Galera has secured funding through private financings and a public listing on the NASDAQ under the symbol GRTX. The company collaborates with academic research centers and clinical investigators in the United States, and it is positioning itself for potential international partnerships to expand development and commercialization efforts. Under the guidance of a team of seasoned biotechnology executives and drug development scientists, Galera aims to translate its redox-modulating platform into new treatments for patients with high-unmet-need respiratory and systemic conditions.